Clinical research

Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial

EuroIntervention 2007;2:426-434 - DOI10.4244/EIJV2I4A78.

Bernard Chevalier
Bernard Chevalier*1, MD; Patrick W. Serruys2, MD, PhD, FACC, FESC; Sigmund Silber3, MD, PhD, FESC; Eulogio Garcia4, MD; Harry Suryapranata5, MD, PhD, FACC, FESC; Karl Hauptmann6, MD; William Wijns7, MD, PhD, FESC; Gerhard Schuler8, MD; Farzin Fath-Ordoubadi9, BSc, MB BCh, MRCP; Stephen Worthley10, MBBS, PhD, FRACP; Leif Thuesen11, MD; Ian Meredith12, MBBS, PhD, FRACP; Marco Bressers13, MSc; Hirofumi Nagai14, MD, Dragica Paunovic15, MD; for the Nobori 1 Clinical Investigators
1. Centre Cardiologique du Nord, Saint-Denis, France; 2. Erasmus MC, Rotterdam, The Netherlands; 3. Kardiologische Gemeinschaftspraxis und HKL, Munich, Germany; 4. Gregorio Marañón, Madrid, Spain; 5. Isala Clinic, Zwolle, The Netherlands; 6. Krankenhaus d

Background: We studied the Nobori™ coronary stent coated with a bioabsorbable polymer and the anti-proliferative agent Biolimus A9 which may reduce neointimal formation.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

drug eluting stentsbiolimus a9randomised trial
Read next article
Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era <br />A pooled analysis on 340 patients treated at three European referral centres

Latest news